Key result
Personalized therapy targets myocardial no-reflow, which affects up to 50% of STEMI patients.
Why the study?
No-reflow after primary PCI in STEMI patients has a multifactorial pathogenesis and variable response to treatment, necessitating personalized management strategies.
Answers are grounded in this paper and cite their sources.
This review proposes a personalized management approach for myocardial no-reflow in STEMI patients based on individual pathogenetic mechanisms.
In a variable proportion of patients presenting with ST-segment elevation myocardial infarction, ranging from 5% to 50%, primary percutaneous coronary intervention achieves epicardial coronary artery reperfusion but not myocardial reperfusion, a condition known as no-reflow. Of note, no-reflow is associated with a worse prognosis at follow-up. The phenomenon has a multifactorial pathogenesis including: distal embolization, ischemia-reperfusion injury, and individual predisposition of coronary microcirculation to injury. Moreover, it is spontaneously reversible in some patients, thus suggesting that it might be amenable to treatment also when we fail to prevent it. Several recent studies have shown that biomarkers and other easily available clinical parameters can predict the risk of no-reflow and can help in the assessment of the multiple mechanisms of the phenomenon. Several therapeutic strategies have been tested for the prevention and treatment of no-reflow. In particular, thrombus aspiration before stent implantation prevents distal embolization and has been recently shown to improve myocardial perfusion and clinical outcome as compared with the standard procedure. However, it is conceivable that the relevance of each pathogenetic component of no-reflow is different in different patients, thus explaining the occurrence of no-reflow despite the use of mechanical thrombus aspiration. Thus, in this review article, for the first time, we propose a personalized management of no-reflow on the basis of the assessment of the prevailing mechanisms of no-reflow operating in each patient.
No takes yet. Share an insight, caveat, or question.
Niccoli et al. (2009) conducted a review in ST-segment elevation myocardial infarction with no-reflow. Personalized management of no-reflow was evaluated. Myocardial no-reflow occurs in 5% to 50% of STEMI patients after primary PCI, prompting the proposal of a personalized management strategy based on individual pathogenetic mechanisms.
Synapse has enriched 10 related papers. Consider them for comparative context: